Podium to Practice: SABCS® 2025 – Her2climb-05
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Studies / Trials Discussed
GS1-01 – Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer
Studies/trials discussed:
GS1-01 – Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.